Safety, Tolerability, and Pharmacokinetics Study of NDX-1017
- Conditions
- Alzheimer Disease
- Interventions
- Drug: NDX-1017Drug: Placebo
- Registration Number
- NCT03298672
- Lead Sponsor
- Athira Pharma
- Brief Summary
This Phase 1 randomized, placebo-controlled, double-blinded, first-in-human study will evaluate safety, tolerability, and pharmacokinetics of single and multiple ascending doses of NDX-1017 in healthy young and elderly subjects, and elderly subjects with amnestic mild cognitive impairment (MCI), Alzheimer's disease (mild, mild-to-moderate, or moderate), or mixed dementia with Alzheimer's and vascular components (mild, mild-to-moderate, or moderate).
- Detailed Description
NDX-1017 is being developed for the treatment of Alzheimer's disease (AD).
This Phase 1 randomized, placebo-controlled, double-blinded, first-in-human study will evaluate safety, tolerability, and pharmacokinetics of single and multiple ascending doses of NDX-1017 in healthy young and elderly subjects, and elderly subjects with mild AD. The study contains the following two parts:
Part A:
A single-ascending dose (SAD) study conducted in an inpatient setting for 3 days in healthy young male and healthy elderly male and female volunteers evaluated in up to 7 dose cohorts to identify the maximum tolerated dose (MTD) within the single dose range studied. Up to 56 subjects (aged 18 to 45 years for young and 60 to 85 years for elderly) may be enrolled in Part A.
Part B:
A multiple ascending dose (MAD) study conducted in an inpatient setting for 10 days in male or female healthy elderly volunteers (aged 60 to 85 years) or subjects with amnestic mild cognitive impairment (MCI), Alzheimer's disease (mild, mild-to-moderate, or moderate), or mixed dementia with Alzheimer's and vascular components (mild, mild-to-moderate, or moderate) (aged 40 to 85 years) in up to 6 dose cohorts that were proven tolerable in the SAD part of the study to identify the MTD within the multiple dose range studied. Up to 44 subjects (aged 40 to 85 years) may be enrolled in Part B.
Subjects will be screened for eligibility within 28 days (or 90 days for amnestic MCI, Alzheimer's Disease, or mixed dementia with Alzheimer's and vascular components) prior to enrollment. Those eligible will be admitted to an inpatient facility for investigational product administration, safety monitoring, and collection of blood or urine for pharmacokinetic evaluations.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 88
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SEQUENTIAL
- Arm && Interventions
Group Intervention Description NDX-1017 NDX-1017 NDX-1017 will be administered via subcutaneous injection Placebo Placebo Placebo will be administered via subcutaneous injection
- Primary Outcome Measures
Name Time Method Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]. Up to 20 days Safety and tolerability of single or multiple ascending doses of NDX-1017 as measured by vital signs and clinical laboratory measurements.
- Secondary Outcome Measures
Name Time Method Plasma concentration at the end of the dosing interval (Ctrough). Samples collected at predetermined timepoints within 48 hours post-dose. Ctrough will be determined from the last plasma sample prior to the following dose (MAD only).
Half-life (t1/2). Samples collected at predetermined timepoints within 48 hours post-dose. t1/2 will be determined from all collected plasma samples from baseline through up to 48 hours post-dose.
Maximum observed plasma concentration (Cmax). Samples collected at predetermined timepoints within 48 hours post-dose. Cmax will be determined from all collected plasma samples from baseline through up to 48 hours post-dose.
Time to maximum observed plasma concentration (Tmax). Samples collected at predetermined timepoints within 48 hours post-dose. Tmax will be determined from all collected plasma samples from baseline through up to 48 hours post-dose.
Area under the plasma concentration time curve (AUC). Samples collected at predetermined timepoints within 48 hours post-dose. AUC will be determined from all collected plasma samples from baseline through up to 48 hours post-dose.
Trial Locations
- Locations (1)
Biotrial Inc.
🇺🇸Newark, New Jersey, United States